AU2021224912A1 - Bacteriophage compositions for treating Staphylococcus infection - Google Patents

Bacteriophage compositions for treating Staphylococcus infection Download PDF

Info

Publication number
AU2021224912A1
AU2021224912A1 AU2021224912A AU2021224912A AU2021224912A1 AU 2021224912 A1 AU2021224912 A1 AU 2021224912A1 AU 2021224912 A AU2021224912 A AU 2021224912A AU 2021224912 A AU2021224912 A AU 2021224912A AU 2021224912 A1 AU2021224912 A1 AU 2021224912A1
Authority
AU
Australia
Prior art keywords
bacteriophage
seq
polynucleotide sequence
composition
identity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021224912A
Other languages
English (en)
Inventor
Stacey Lynn KOLAR
Brian C. Varnum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Armata Pharmaceuticals Inc
Original Assignee
Armata Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Armata Pharmaceuticals Inc filed Critical Armata Pharmaceuticals Inc
Publication of AU2021224912A1 publication Critical patent/AU2021224912A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021224912A 2020-02-18 2021-02-18 Bacteriophage compositions for treating Staphylococcus infection Pending AU2021224912A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062978006P 2020-02-18 2020-02-18
US62/978,006 2020-02-18
PCT/US2021/018623 WO2021168147A1 (en) 2020-02-18 2021-02-18 Bacteriophage compositions for treating staphylococcus infection

Publications (1)

Publication Number Publication Date
AU2021224912A1 true AU2021224912A1 (en) 2022-09-01

Family

ID=77272316

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021224912A Pending AU2021224912A1 (en) 2020-02-18 2021-02-18 Bacteriophage compositions for treating Staphylococcus infection

Country Status (8)

Country Link
US (4) US20210252083A1 (https=)
EP (1) EP4106782A4 (https=)
JP (1) JP2023513934A (https=)
CN (1) CN115397447A (https=)
AU (1) AU2021224912A1 (https=)
CA (1) CA3171467A1 (https=)
IL (1) IL295408A (https=)
WO (1) WO2021168147A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872519B1 (en) * 1999-04-27 2005-03-29 Mirus Bio Corporation In vitro process for selecting phage resistant to blood inactivation
US11214773B2 (en) * 2015-09-24 2022-01-04 San Diego State University (Sdsu) Foundation Antibacterial and protective bacteriophage formulations and methods for making and using them
CN110719784A (zh) * 2017-02-13 2020-01-21 阿玛塔制药公司 治疗性噬菌体组合物
EP3372085A1 (en) * 2017-03-08 2018-09-12 Pherecydes Pharma Phage therapy
CN112218659A (zh) * 2018-01-02 2021-01-12 阿玛塔制药股份有限公司 用于治疗葡萄球菌感染的治疗性噬菌体组合物

Also Published As

Publication number Publication date
IL295408A (en) 2022-10-01
EP4106782A1 (en) 2022-12-28
WO2021168147A1 (en) 2021-08-26
US20240189373A1 (en) 2024-06-13
US20230092021A1 (en) 2023-03-23
US20260041723A1 (en) 2026-02-12
JP2023513934A (ja) 2023-04-04
CN115397447A (zh) 2022-11-25
US20210252083A1 (en) 2021-08-19
CA3171467A1 (en) 2021-08-26
EP4106782A4 (en) 2024-05-15

Similar Documents

Publication Publication Date Title
RU2234940C2 (ru) Способ лечения стафилококковых инфекций у млекопитающего (варианты)
US20230248789A1 (en) Therapeutic bacteriophage compositions for treating staphylococcus infection
JP7449967B2 (ja) 療法バクテリオファージ組成物
US20190142881A1 (en) Bacteriophage compositions and uses thereof
CN116018154A (zh) 用于治疗假单胞菌属感染的噬菌体组合物
WO2019136108A1 (en) Bacteriophage compositions for treating pseudomonas infections
US20260041723A1 (en) Bacteriophage compositions for treating staphylococcus infection
JP2022538854A (ja) 新規なシータディフェンシンアナログ
US20220160842A1 (en) Method of treating infective endocarditis
Liu et al. RETRACTED: Verapamil increases susceptibility of colistin-resistant Acinetobacter baumannii to colistin
AU2020271116A1 (en) Method of treating and preventing bone and joint infections
EP1671644A2 (en) Pharmaceutical compositions containing Lysostaphin alone or in combination with an antibiiotic for the treatment of Staphylococcal infections
JP2023513934A5 (https=)
HK40040296A (en) Therapeutics bacteriophage compositions for treating staphylococcus infection